If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Assessed by visual inspection under ordinary light |
| Primary analytical method | Reversed-phase liquid chromatography | Purity estimated from peak area at 214 nm |
| Confirmatory method | Mass spectrometry | Observed mass compared with calculated value |
| Powder storage temperature | Minus 20 degrees Celsius | Minus 80 for extended archival periods |
| Solution stability | Hours to days at 2 to 8 degrees Celsius | Influenced by pH, buffer, and concentration |
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
== History == The discovery and characterization of aminopeptidases date back to the early 20th century. The term "aminopeptidase" was first introduced in 1929 by Linderstrøm-Lang and Sato in order to describe enzymes that cleave amino acids from the N-terminus of peptides. In the 1950s and 1960s, the discovery of leucine aminopeptidase (LAP) and aminopeptidase N (APN) marked important milestones in the field. LAP was found to be crucial for protein digestion, while APN was recognized for its role in the regulation of peptide-mediated effects. These discoveries were pivotal in understanding the physiological functions of aminopeptidases and their involvement in health and disease. The subsequent decades saw extensive research into the structure, function, and mechanisms of action of various aminopeptidases. For example, the M1 family of aminopeptidases, which includes puromycin-sensitive aminopeptidase (PSA), was characterized by conserved zinc-dependent sites and exopeptidase motifs. The study of PSA in different model organisms revealed its essential roles in growth and behavior. Mutations in orthologs of PSA in different species were linked to errors in meiosis and reduced viability of embryos. Aminopeptidase N, also known as AP-N or CD13, was extensively characterized for its broad substrate specificity (ability to bind to its targets) and its presence in various tissues such as the brush border membranes of the kidney, small intestine, and placenta.
=== Hematopoietic stem cell transplant === Bronchiolitis obliterans affects up to 5.5% of people who have received HSCT. One of the biggest risk factors after HSCT is the development of GVHD with a 14% risk. Other risk factors post transplant including tobacco use, age of donor, age of recipient, lower baseline FEV1/FVC ratio, non-caucasian race, peripheral and lower circulating IgG levels. Studies have, however, shown mixed results regarding these other risk factors. There has been an association shown between the increased use of peripheral stem cells and the risk of developing bronchiolitis obliterans. Also, research has shown an increased risk for developing the disease within the first year of transplant if the person is infected with respiratory syncytial virus or parainfluenza virus within the first 100 days post transplant.
Because reporter genes such as lacZ, GFP, and luciferase are widely used in standardized plasmid constructs for gene expression studies, well-characterized reporter vectors are preserved as reference materials in public biological resource centres and non-profit repositories such as BCCM/GeneCorner and Addgene, supporting reproducibility in molecular biology research.
If a complexing agent is present in the aqueous phase then it can lower the distribution ratio. For instance, in the case of iodine being distributed between water and an inert organic solvent such as carbon tetrachloride then the presence of iodide in the aqueous phase can alter the extraction chemistry: instead of
Indeed, SIRT3 deacetylates and activates the mammalian mitochondrial acetyl-coA synthetase (AceCS2). Furthermore, SIRT3 and AceCS2 are found complexed with one another, suggesting a critical role for control of AceCS2 activity by SIRT3. Activation of the NMNAT2 enzyme, which catalyze an essential step in the nicotinamide adenine dinucleotide (NAD+) biosynthetic pathway by SIRT3 may be a means of inhibiting axon degeneration and dysfunction.
Sources: en.wikipedia.org
The President directed other U.S. government agencies to put their technical assistance in developing countries under FOA's management as well. USDA in particular transferred OFAR's programs to FOA, while reconstituting the Foreign Agricultural Service for the task of building global markets for U.S. farm products. Administrative functions were consolidated as the various agencies came into FOA, and the Mutual Security Act of July 1953 instructed FOA to reduce personnel by at least 10% within 120 days. A large number of TCA's senior professionals were summarily dismissed, and FOA's administrator mounted an effort to compensate for lower U.S. government staffing by drawing on experts from U.S. universities and private voluntary organizations. The ExIm Bank's lending volume in developing countries was also cut dramatically in 1953. While a "trade not aid" strategy required the U.S. to import more goods from its allies, the administration was unable to convince Congress to liberalize import policy. On the contrary, the main foreign commercial measure taken at this time went in the other direction: the U.S. ramped up subsidies for exports of U.S. agricultural products. The 1953 amendment to the Mutual Security Act and the much larger Agricultural Trade Development and Assistance Act of 1954, known as "PL-480", allowed the U.S. government to buy U.S. farm surpluses and sell them in developing countries for inconvertible local currencies. Much of PL-480's foreign-currency revenue was returned to developing countries as a supplement to U.S. development assistance.
== Side effects == Side effects of methenamine are minor and infrequent, reportedly occurring in fewer than 4% of individuals. They include dyspepsia (upset stomach), abdominal pain, dysuria (painful or uncomfortable urination), nausea, vomiting, diarrhea, headache, rash, and pruritus (itching). The drug is generally very well-tolerated. Rarely, reversibly elevated liver enzymes, including of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), have been reported. Normalization of liver enzymes has occurred with discontinuation or continuation of methenamine. Hypersensitivity reactions have also rarely been reported. It has been said that methenamine, overall, is very safe. Formaldehyde is a known carcinogen, for instance being associated with nasopharyngeal cancer and leukemia. This compound also occurs in small amounts as a contaminant in alcoholic beverages, and is chemically similar to the carcinogenic ethanol (alcohol) metabolite acetaldehyde. Because of the formaldehyde exposure with methenamine, there have been concerns about methenamine's potential carcinogenicity and the possibility that it might increase the risk of cancer, for instance bladder or stomach cancer. No clinical studies have looked directly at the long-term effects of methenamine in this regard. However, there are no published case reports documenting incidence of cancer with methenamine as of 2023. Moreover, animal studies have found no evidence of long-term carcinogenicity with oral methenamine.
While other plants have δ15N values that range from 2 to 6‰, legumes have lower 14N/15N ratios (close to 0‰, i.e. atmospheric N2) because they can fix molecular nitrogen, rather than having to rely on soil nitrates and nitrites. Therefore, one potential explanation for lower δ15N values in human remains is an increased consumption of legumes or animals that eat them. 15N values increase with meat consumption, and decrease with legume consumption. The 14N/15N ratio could be used to gauge the contribution of meat and legumes to the diet.
RNA interference (RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. Historically, RNAi was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. The detailed study of each of these seemingly different processes elucidated that the identity of these phenomena were all actually RNAi. Andrew Fire and Craig Mello shared the 2006 Nobel Prize in Physiology or Medicine for their work on RNAi in the nematode worm Caenorhabditis elegans, which they published in 1998. Since the discovery of RNAi and its regulatory potentials, it has become evident that RNAi has immense potential in suppression of desired genes. RNAi is now known as precise, efficient, stable and better than antisense therapy for gene suppression. Antisense RNA produced intracellularly by an expression vector may be developed and find utility as novel therapeutic agents. Two types of small ribonucleic acid (RNA) molecules, microRNA (miRNA) and small interfering RNA (siRNA), are central to components to the RNAi pathway. Once mRNA is degraded, post-transcriptional silencing occurs as protein translation is prevented. Transcription can be inhibited via the pre-transcriptional silencing mechanism of RNAi, through which an enzyme complex catalyzes DNA methylation at genomic positions complementary to complexed siRNA or miRNA.
=== Nonalcoholic fatty liver disease and heart failure === Recently, it is reported that in non-alcoholic fatty liver disease and heart failure, decreased CL levels and change in acyl chain composition are also observed in the mitochondrial dysfunction. However, the role of CL in aging and ischemia/reperfusion is still controversial.
Sources: en.wikipedia.org
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.
Dry powder is markedly more stable than solution and is usually held frozen and desiccated. Room temperature exposure over days degrades it more slowly than most people assume, but long-term integrity favors freezer storage. Light protection is recommended regardless of temperature.
Methods, columns, gradients, and detection wavelengths are not standardized across laboratories. Some figures describe only the main peak area at one wavelength and ignore water, salts, or counter-ions. Without stated conditions, comparing reported percentages across sources is unreliable.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.